Parkwood Institute
London, Ontario, N6C0A7, Canada
NCT Number: NCT06843109
This is a prospective, observational, case control study in a real-world cohort of patients referred by a primary care physician to a tertiary memory clinic for cognitive concerns. This study's main objective is to determine the effect of using standardized criteria (based on eligibility for disease modifying treatment (DMT)) to triage patients towards biological staging of disease with biomarker testing.
Interested in participating?
Request Info55 year–80 year
All sexes
Observational
London, Ontario, N6C0A7, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: through study completion, approximately 1 year
Analysis of resources needed to conduct testing including personnel required, time requirements, space, and resources/equipment
Time frame: through study completion, approximately one year
Measured by investigator pre and post biomarker questionnaire indicating clinical suspicion, confidence of clinical suspicion, tests to be ordered, and management plan.
Time frame: through study completion, approximately one year
Determined by Participant Pre and Post Biomarker Questionnaire
Time frame: through study completion, approximately one year
Measured by the percent agreement between plasma biomarker and CSF results and amyloid PET results
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Other
Biomarkers as Part of Diagnostic Workup for Alzheimer's Disease: A Feasibility Study in a Canadian Memory Clinic
Acronym: BioMIND
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06953167
Alzheimer Disease, Alzheimer's Disease (AD)
London, United Kingdom
View Trial DetailsNCT06934720
Alzheimer's Disease (AD), Behavior
View Trial DetailsNCT06898424
Alzheimer Disease, Alzheimer Type Dementia
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06922188
Alzheimer Disease, Alzheimer's Disease (AD)
Seattle, Washington, United States
View Trial Details